Armenian Bioinformatics Institute shared a post on Facebook:
“New Publication!
We’re happy to share a new paper from ABI’s Binder Lab, published in Oncogene:
MSS metastatic colorectal cancer rarely responds to immunotherapy, making it one of the most challenging cancers to treat. Using self-organizing map machine learning, our team analyzed tumor biopsies from patients treated with botensilimab and balstilimab (Agenus) and identified four molecular tumor types, each with a distinct immune landscape. Immune-enriched and mesenchymal-like tumors showed better responses and longer survival. The study also points to an interferon and APOBEC3 signal, invisible to standard mutation-burden tests, as a key driver of immune recognition.
The work was carried out in collaboration with Agenus as part of a phase I clinical trial. Congratulations to the whole team!”
Title: “Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.”
Authors: Konecny T, Zadirako N, Grigoryan A, Tamazyan M, Mnatsakanyan S, Stepanyan L, Loeffler-Wirth H, Bourdelais S, Mednick G, Delepine C., Chand D, Binder H.
Other articles about Metastatic Colorectal Cancer on OncoDaily.